drugset / Trial / NCT00456027
Safety of Diamyd® in Patients With LADA (Latent Autoimmune Diabetes in Adult)
NaSingle-groupOpen-labelTreatment
Summary
This is a study to investigate the safety of 20ug Diamyd® (rhGAD65 formulated in Alhydrogel®), administered subcutaneously four weeks apart in patients with Latent Autoimmune Diabetes in Adult (LADA).
Timeline
- Start
- 2004-12
- Primary completion
- 2008-03
- Completion
- 2008-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GLUTAMATE DECARBOXYLASE 2 | Vaccine | 20 ug | Subcutaneous |